Table 2 Clinicopathological characteristics of patients grouped by Testin expression

Age (years)

0.425

≤ 65

39(54.2%)

52(60.5%)

91(57.6%)

>65

33(45.8%)

34(39.5%)

67((42.4%)

Gender

0.129

Male

60(83.3%)

63(73.3%)

123(77.8%)

Female

12(16.7%0

23(26.7%)

35(22.2%)

Maximum tumor diameter (cm)

0.494

≤ 3

25(34.7%)

35(40.7%)

60(37.95%)

3 < d ≤ 5

26(36.1%)

34(39.5%)

60(37.95%)

5 < d ≤ 7

10(13.9%)

10(11.6%)

20(12.7%)

> 7

11(15.3%)

7(8.2%)

18(11.4%)

Histological type

0.580

Squamous

32(44.4%)

45(52.3%)

77(48.7%)

Adenocarcinoma

32(44.4%)

34(39.5%)

66(41.8%)

others

8(11.2%)

7(8.2%)

15(9.5%)

Tumor differentiation

0.642

Low-medium

42(58.3%)

47(54.7%)

89(56.3%)

Medium-high

30(41.7%)

39(45.3%)

69(43.7%)

pN status

0.006

N0

29(40.3%)

60(69.8%)

89(56.3%)

N1

19(26.4%)

15(17.4%)

34((21.5%)

N2-N3

24(33.3%)

11(12.8%)

35(22.2%)

Ki-67

0.162

≤30

33(45.8%)

30(34.9%)

63(39.9%)

>30

39(54.2%)

56(65.1%)

95(60.1%)

TNM stage

0.0012

I

8(9.4%)

24(32.9%)

32(20.3%)

II

36(42.4%)

22(30.1%)

58(36.7%)

III

41(48.2%)

27(37.0%)

68(43.0%)

Invasion

0.0055

Yes

41(56.9)

30(34.9)

71(44.9%)

NO

31(43.1)

56(65.1)

87(55.1%)

Group

0.472

NSCLC only

26(36.1%)

39(45.3%)

65(41.1%)

PRISm

17(23.6%)

19(22.1%)

36(22.8%)

COPD

29(40.3%)

28(32.6%)

57(36.1%)